

Effects of TSPO and STAR inhibitors on cell death in a cardiomyocyte model of hypoxia-reoxygenation

Juliette Bréhat, Shirin Leick, Leeyah Issop, Nario Tomishige, Toshihide

Kobayashi, Bijan Ghaleh, Sandrine Pons, Didier Morin

▶ To cite this version:

Juliette Bréhat, Shirin Leick, Leeyah Issop, Nario Tomishige, Toshihide Kobayashi, et al.. Effects of TSPO and STAR inhibitors on cell death in a cardiomyocyte model of hypoxia-reoxygenation. Printemps de la cardiologie, May 2021, Paris, France. hal-03357945

HAL Id: hal-03357945 https://hal.science/hal-03357945

Submitted on 1 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.







ÉCOLE DOCTORALE Innovation thérapeutique : du fondamental à l'appliqué



Effects of TSPO and STAR inhibitors on cell death in a cardiomyocyte model of hypoxia-reoxygenation

J. Bréhat^{*1}, S. Leick¹, L. Issop¹, N. Tomishige², T. Kobayashi², B. Ghaleh¹, S. Pons¹, D. Morin¹

¹ U955 IMRB Equipe Ghaleh, INSERM, Créteil, France

²Biophotonique des interactions moléculaires et cellulaires, Université de Strasbourg CNRS UMR 7021, Strasbourg, France


INTRODUCTION

We previously demonstrated that reperfusion of an ischemic myocardium induces an increase in mitochondrial cholesterol (Chol) content accompanied by a generation of oxysterols. The translocator protein (TSPO) and the steroid acute regulatory protein (STAR) are involved in Chol transport at the mitochondrial membrane in steroidogenic tissues but in the heart their roles remain uncertain. The TSPO ligand 4'-chlorodiazepam (4'CDZ) has been **Cholestérol** demonstrated to inhibit STAR and sterol mitochondrial accumulations and to reduce infarct size. StAR 37 kDa TSPO ANA These data suggest that targeting mitochondrial sterol accumulation could participate to the protective effects of TSPO ligands.

> The aim of this study was to analyze the mechanisms and the role of the mitochondrial Chol transport in cell death with a cardiomyocyte model of hypoxia-reoxygenation (HR).

— METHODS

AC16 human cardiomyocytes were submitted to different durations of hypoxia (1% O_2) followed by reoxygenation (21% O_2) to achieve 50% mortality. Cells were then treated at reoxygenation with 4'CDZ and novel TSPO and STAR inhibitors, known to delay steroidogenesis in vitro by targeting Chol specific binding sites of these proteins (CRAC and START, respectively). Cell mortality was assessed with MTT and crystal violet assay and Chol was identified with thin layer chromatography and fluorescent microscopy.



A. 6h hypoxia followed by 2 h **39±10%** reoxygenation induces mortality in AC16 cells (MTT assay)


B. 6h hypoxia followed by 14 h reoxygenation 26±2% induces mortality in AC16 cells (MTT assay)

C. 14h hypoxia followed by 2 h 53±3% induces reoxygenation mortality in AC16 cells (MTT assay)

D. 14h hypoxia induces 37±6% mortality, **2h reoxygenation induces** further mortality 51±3% in AC16 cells (crystal violet assay)


StAR

27 kDa




2 – Behavior of cholesterol content during HR –

A. Whole cell cholesterol content is not modified by HR




B. Distribution of membrane cholesterol is modified by HR Red : Membrane cholesterol (**D4-mCherry**) Blue : Nucleus (Hoechst)



3 – Effect of TSPO and STAR inhibitors on cell. mortality at reperfusion

A. Chemical structure of cholesterol (endogen TSPO and STAR ligand), 4'chlorodiazepam : 4'CDZ (TSPO ligand), CRAC inhibitor A-triol : iCRAC triol (TSPO inhibitor), START inhibitor A-diol : iSTART diol (STAR inhibitor), CRAC **inhibitor benzamide : iCRAC benz** (TSPO inhibitor)



-- CONCLUSION

This preliminary study suggests that TSPO ligands do not exert cardioprotection through a direct action on cardiomyocytes. This conclusion needs to be confirmed with the use of adult primary cardiomyocytes.